DIGITAL TRANSFORMATION AND REGULATORY CONSIDERATIONS FOR BIOPHARMACEUTICAL AND HEALTHCARE MANUFACTURERS

DIGITAL DATA, INSIGHTS, METRICS AND ANALYTICS

Tim Sandle
Digital Transformation and Regulatory Considerations for Biopharmaceutical and Healthcare Manufacturers

Volume 2
Digital Data, Insights, Metrics and Analytics

To order the book, please visit: go.pda.org/TRANS2

Tim Sandle

PDA
Bethesda, MD, USA

DHI Publishing, LLC
River Grove, IL, USA
CONTENTS

1 THE NEW NORMAL? DIGITAL TECHNOLOGIES: TRANSFORMING DATA ANALYTICS AND THE LABORATORY THROUGH DIGITAL TECHNOLOGY AND THE NEW WORKPLACE

Introduction ........................................................................................................................................ 1
Summary ........................................................................................................................................ 13
References ....................................................................................................................................... 13

2 DIGITALIZING THE LABORATORY: FROM LIMS TO AUTOMATED INSTRUMENTATION ...................... 17

Introduction ................................................................................................................................... 17
Digital transformation of the laboratory ........................................................................................... 19
LIMS and the lean laboratory .......................................................................................................... 20
LIMS design ................................................................................................................................... 25
Data security ................................................................................................................................... 27
LIMS validation and implementation ............................................................................................... 29
LIMS administrator .......................................................................................................................... 36
LIMS: Data integrity and compliance ............................................................................................. 37
LIMS and sample management ....................................................................................................... 41
Equipment interfaces ....................................................................................................................... 43
Auditing LIMS ................................................................................................................................. 43
Supplier ............................................................................................................................................ 45
Ownership ....................................................................................................................................... 45
Compliance standards ..................................................................................................................... 46
LIMS: What to audit? ....................................................................................................................... 52
Risk assessing LIMS ....................................................................................................................... 62
Digital Transformation and Regulatory Considerations

Data governance for LIMS.................................................................63
Summary .......................................................................................63
References ...................................................................................65

3 AUTOMATING THE LABORATORY........................................69
Introduction .................................................................................69
Laboratory automation .................................................................70
Electronic laboratory notebooks ..................................................79
Summary .....................................................................................86
References ..................................................................................87

4 DIGITAL LABORATORY IN PRACTICE:
RAPID MICROBIOLOGICAL METHODS .........................91
Introduction ................................................................................91
Types of microbiological methods .............................................93
Selection of rapid microbiological methods ................................95
Variability with microbiological methods ....................................97
Factors to consider for experimental design ..............................101
Validation parameters ...............................................................109
Rapid and alternative microbiological methods .......................116
Summary ..................................................................................119
References .................................................................................120
Appendix: Flow chart for the design of
microbiological experiments ...................................................124

5 DEVELOPING TRENDS WITH E-LEARNING
IN THE PHARMACEUTICAL WORKPLACE ..................125
Introduction ...............................................................................125
What is e-learning? ..................................................................126
Shifting responsibilities ..............................................................127
Learning styles .........................................................................128
Off-site and remote learning ....................................................129
Virtual reality ............................................................................130
Augmented reality .................................................................130
Electronic learning boards ......................................................131
Other applications of digital learning at work .........................132
E-learning case study #1: Cleaning and disinfection ..............134
E-learning case study #2: Healthcare .......................................140
E-learning challenges ..............................................................144
When e-learning goes wrong ................................................146

www.pda.org/bookstore
Delving into learning with management analytics ............................................. 151
Summary .................................................................................................................. 153
References ............................................................................................................... 154

6 APPROACHING THE VIRTUAL REGULATORY INSPECTIONS: WHAT TO EXPECT, HOW TO PREPARE AND HOW TO PARTICIPATE ......................... 157
Introduction ............................................................................................................. 157
Regulatory positions on remote inspections .......................................................... 159
Technical requirements .......................................................................................... 162
What to expect from a remote inspection? .............................................................. 165
Approaching video conferencing ........................................................................... 174
Regulatory concerns during remote inspections ..................................................... 176
Auditing suppliers ................................................................................................... 177
Submission of information ....................................................................................... 179
Summary ................................................................................................................. 179
Appendix: Examples of information requested in advance by an inspector (based on FDA remote audit requests from 2020) ........................................ 181

7 DIGITAL TRANSFORMATIVE TECHNOLOGIES FOR THE PHARMACEUTICAL SECTOR OFFICE ................. 189
Introduction ............................................................................................................. 189
Remote working – an overview .............................................................................. 191
Cloud computing ..................................................................................................... 195
Bring-your-own-device ........................................................................................... 196
Remote working practicalities ................................................................................ 196
Downsides of remote working .............................................................................. 204
Tips for effective home working ............................................................................ 210
Virtual conferences ................................................................................................ 212
Summary .................................................................................................................. 212
References .............................................................................................................. 213

8 DATA INTEGRITY CONSIDERATIONS FOR THE DIGITAL TRANSFORMATION WAVE ......................... 219
Introduction ............................................................................................................. 219
Computerized systems ............................................................................................ 222
Computerized systems audits .................................................................................. 223
Supplier ...................................................................................................................... 224
Ownership ............................................................................................................... 224
Compliance standards .............................................................................................. 226
Computerized System Validation ................................................................. 227
What to audit? .............................................................................................. 234
Five step approach ...................................................................................... 250
Significant non-compliances ..................................................................... 251
Data integrity ............................................................................................... 252
Data and data governance ......................................................................... 255
Regulatory perspectives ............................................................................ 257
Data integrity and digital transformation .................................................. 262
Risks ............................................................................................................. 264
Risk assessment .......................................................................................... 266
Vendor questionnaires ................................................................................ 270
Summary ...................................................................................................... 274
References ................................................................................................... 277

9 CALL FROM AFAR: TELEHEALTH AND THE COMMUNICATION OF HEALTH .............................................. 283
Introduction ................................................................................................ 283
Defining telehealth ...................................................................................... 285
Growing usage of remote health delivery .................................................. 286
Pharmaceuticals and telehealth .................................................................. 287
Measuring effectiveness .............................................................................. 288
Critiques of telehealth ................................................................................ 289
Case study – health advice at home ............................................................ 291
E-prescribing ............................................................................................... 293
Summary ...................................................................................................... 295
References ................................................................................................... 296

10 DIGITAL DATA: RESEARCHING, SEARCHING, AND HANDLING .......................................................... 299
Introduction ................................................................................................ 299
Content creation: Archiving and indexing data for research .................... 300
Digital research challenges ......................................................................... 303
Digital research sources ............................................................................. 307
Open access and open data ....................................................................... 310
Where to search for research papers? ......................................................... 315
Open access databases and search platforms .......................................... 315
Data governance .......................................................................................... 320
Summary ...................................................................................................... 320
References ................................................................................................... 321
Contents

11 QUESTIONS TO ANSWER? DATA PRIVACY, DATA OWNERSHIP, AND DATA SECURITY ............... 325
Introduction ...................................................................................................................... 325
Reaching a common understanding ............................................................................ 328
Data governance ............................................................................................................ 329
Data privacy ...................................................................................................................... 331
Deepfakes .......................................................................................................................... 343
Data ownership ............................................................................................................... 345
Cybersecurity, data breaches and data loss ................................................................. 348
Summary ............................................................................................................................ 369
References ......................................................................................................................... 371

12 WHY DIGITAL TRANSFORMATION PROJECTS FAIL (AND HOW THEY MIGHT SUCCEED) .......... 379
Introduction ...................................................................................................................... 379
State of digital transformation in pharmaceuticals and healthcare ...................... 380
Regulatory perspectives ................................................................................................. 381
Computerized systems ................................................................................................... 382
Lack of a multi-dimensional approach ........................................................................ 382
Dangers of over-predicting ......................................................................................... 383
Lack of up-front commitment ...................................................................................... 384
Centralization and being “big” .................................................................................. 385
People and workplace culture .................................................................................... 386
Failure to identify points of friction ........................................................................... 388
Lack of cybersecurity skills ....................................................................................... 390
Failing to map out the digital lifecycle ........................................................................ 391
Inability to “know the customer” ............................................................................... 392
Legacy technology .......................................................................................................... 392
Inadequate understanding of computerized systems ................................................. 393
Ensuring success ........................................................................................................... 398
Summary ............................................................................................................................ 402
References ......................................................................................................................... 403

INDEX .................................................................................................................................. 407
About the Book

Volume 1 addresses numerous topics including building a digital company, big data analytics, advances in Process Analytical technology electronic batch records, Block Chain, technologies to address counterfeit medicines and many other topics. Volume 2 goes on to spell out how pharmaceutical and healthcare manufacturers have been embracing digital technologies as part of the transformation of their business models and to contextualize the current and future-state advancements in the context of the COVID-19 situation of 2020 – the pandemic that impacted every business around the globe.

Details are offered on the various laboratory functions:
- new model healthcare
- ways to use digital data including root cause investigations
- office technology
- data integrity
- digital data research
- search and handling
- protecting ownership security
- e-learning, virtual inspections
- and many other relevant topics.

The after-effect of the coronavirus measures has been to shift the boundaries between the healthcare businesses and workforce, including more remote working, and the way that companies need to collate and share data internally, with contractors, and sometimes with competitors. Digitalization of data and the analysis of data using digital tools is the new normal.

The disruption caused by the digital transformation of pharmaceuticals and healthcare is not static; it is evolving, and it will continue to evolve. Across the chapters, these volumes put down a marker for where things are currently, where they are likely to develop, and the challenges that adopters face, in terms of practicalities and in maintaining GMP compliance.

About the Author

Dr. Tim Sandle has over 25 years’ experience in microbiological research and biopharmaceutical processing. He is Head of Microbiology and Sterility Assurance at Bio Products Laboratory, UK and a visiting tutor with the School of Pharmacy and Pharmaceutical Sciences, University of Manchester. In addition, Dr. Sandle serves on several national and international committees relating to pharmaceutical microbiology and cleanroom contamination control, including Pharmaceutical Microbiology Interest Group (Pharmig) and PDA technical working groups. He is the author or coauthor of several PDA/DHI texts as well as a contributor to others.